E-LIB Suche - Ergebnisse für: Hanžel, J

1

DOP11 Disease clearance after 16 weeks of treatment with ve..:

Jairath, V ; Zou, G ; Adsul, S...
Journal of Crohn's and Colitis. 18 (2024) Supplement_1 - p. i92-i93 , 2024

Link: https://doi.org/10.1093/..

2

P702 Clinical and biomarker remission is maintained after s..:

Pintar, S ; Hanžel, J ; Smrekar, N...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i834-i835 , 2023

Link: https://doi.org/10.1093/..

3

P311 Reliability of computed tomography enterography for ev..:

Rieder, F ; Ma, C ; Hanzel, J...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i453-i453 , 2023

Link: https://doi.org/10.1093/..

4

P495 Vedolizumab trough concentrations and histological rem..:

Hanzel, J ; Baert, F ; Löwenberg, M...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i625-i626 , 2023

Link: https://doi.org/10.1093/..

5

P720 Drug survival of first-line biologics in inflammatory ..:

Hanzel, J ; Supovec, E ; Smrekar, N...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i850-i851 , 2023

Link: https://doi.org/10.1093/..

6

P672 Switching out of class or to another anti-TNF agent is..:

Anjie, S ; Hanžel, J ; Gecse, K B..
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i803-i804 , 2023

Link: https://doi.org/10.1093/..

7

P793 Infliximab and prevention of colectomy in acute severe..:

Wang, Z ; Afif, W ; Hanžel, J...
Journal of Crohn's and Colitis. 17 (2023) Supplement_1 - p. i925-i926 , 2023

Link: https://doi.org/10.1093/..

8

P041 Characterization of cytokine and drug concentrations i..:

Van Oostrom, J ; Hanzel, J ; Verstockt, B...
Journal of Crohn's and Colitis. 16 (2022) Supplement_1 - p. i157-i158 , 2022

Link: https://doi.org/10.1093/..

9

DOP63 Real World Effectiveness, Safety and Pharmacokinetics..:

Volkers, A ; Straatmijer, T ; Duijvestein, M...
Journal of Crohn's and Colitis. 16 (2022) Supplement_1 - p. i108-i109 , 2022

Link: https://doi.org/10.1093/..

10

P344 Effectiveness and safety of switching patients with in..:

Hanzel, J ; Strik, A ; Gecse, K..
Journal of Crohn's and Colitis. 15 (2021) Supplement_1 - p. S367-S368 , 2021

Link: https://doi.org/10.1093/..

11

DOP74 Effectiveness of dose escalation in Crohn's disease p..:

Kopylov, U ; Hanzel, J ; Liefferinckx, C...
Journal of Crohn's and Colitis. 14 (2020) Supplement_1 - p. S111-S112 , 2020

Link: https://doi.org/10.1093/..

12

P177 Lower vedolizumab trough levels before interval shorte..:

Ungar, B ; Malickova, K ; Hanžel, J...
Journal of Crohn's and Colitis. 14 (2020) Supplement_1 - p. S226-S227 , 2020

Link: https://doi.org/10.1093/..

13

P686 Neither high infliximab maintenance doses nor high tro..:

Kurent, T ; Koren, U ; Hanzel, J...
Journal of Crohn's and Colitis. 13 (2019) Supplement_1 - p. S463-S464 , 2019

Link: https://doi.org/10.1093/..

14

N17 Frequency of infliximab-induced skin lesions and their ..:

Bobnar Sekulic, C ; Polanc, T ; Koren, U...
Journal of Crohn's and Colitis. 13 (2019) Supplement_1 - p. S564-S565 , 2019

Link: https://doi.org/10.1093/..

15

P603 Vedolizumab trough levels at Week 6 predict endoscopic..:

Hanžel, J ; Sever, N ; Ferkolj, I...
Journal of Crohn's and Colitis. 12 (2018) supplement_1 - p. S414-S414 , 2018

Link: https://doi.org/10.1093/..